Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Docosapentaenoic acid" patented technology

Docosapentaenoic acid (DPA) designates any straight chain 22:5 fatty acid, that is a straight chain open chain type of polyunsaturated fatty acid (PUFA) which contains 22 carbons and 5 double bonds. DPA is primarily used to designate two isomers, all-cis-4,7,10,13,16-docosapentaenoic acid (i.e. 4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid) and all-cis-7,10,13,16,19-docosapentaenoic acid (i.e. 7Z,10Z,13Z,16Z,19Z-docosapentaenoic acid). They are also commonly termed n-6 DPA and n-3 DPA, respectively; these designations describes the position of the double bond being 6 or 3 carbons closest to the (omega) carbon at the methyl end of the molecule and is based on the biologically important difference that n-6 and n-3 PUFA are separate PUFA classes, i.e. the omega-6 fatty acids and omega-3 fatty acids, respectively. Mammals, including humans, can not interconvert these two classes and therefore must obtain dietary essential PUFA fatty acids from both classes in order to maintain normal health (see essential fatty acids).

Application of docosapentaenoic acid in preparation of medicine for preventing and / or treating systemic lupus erythematosus

The invention discloses application of docosapentaenoic acid or medicinal salt thereof in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The invention aims to provide novel application of docosapentaenoic acid in treatment of systemic lupus erythematosus. In view of various immune abnormalities existing in the systemic lupus erythematosus morbidity process, the docosapentaenoic acid has potential application value in the field of systemic lupus erythematosus treatment due to the effects of regulating immune cell functions and improving immune microenvironment.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Plasma metabolism marker combination for predicting human aging and application thereof

The invention discloses a biomarker composition for predicting the biological age or aging state of an individual, and the biomarker composition comprises tetracosyl saturated fatty acid / tetracosyl monounsaturated fatty acid phosphatidylcholine (PC 24: 0 / 14: 1), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine- The invention relates to a pharmaceutical composition for the preparation of a pharmaceutical composition, which comprises the following components in parts by weight: 20: 0 / 22: 5, 20 / docosapentaenoic acid monohexosyl sphingosine amide (HexCer 20: 0 / 22: 5), trigonelline, lithocholic acid glycine (Lithocholic acid glycine), and octadecanoic saturated fatty acid / octadecanoic monounsaturated fatty acid phosphatidylcholine (PC 18: 0 / 18: 1). The biomarker can be used for accurately characterizing the aging state of an organism, and provides a strategy for early screening, intervention evaluation, accurate health management and the like of related diseases of the elderly.
Owner:UNIV OF SCI & TECH OF CHINA

Omega-3 compositions and methods relating thereto

The present invention provides for a water-soluble composition comprising at least one source of Omega-3 comprising at least one Omega-3 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and alpha-linolenic acid (ALA), and micelle-promoting agents comprising one or more of carrier oils, solvents, emulsiiiers and antioxidants, in order to promote an increase in biovailability of the Omega-3 Source of at least two times.
Owner:PHARMAKO BIOTECH PTY LTD

Specific metabolism marker combination for identifying drying mode of high-calcium vegetable ox ear powder and application of specific metabolism marker combination

The invention belongs to the technical field of food processing and quality safety control, and particularly relates to a specific metabolic marker combination for identifying a drying mode of high-calcium vegetable ox ear powder and application of the specific metabolic marker combination. The metabolic marker composition is prepared from 12 kinds of metabolites, namely, larch sibirica flavone, 9-Methyl-arylchromenone, larch resinol, docosapentaenoic acid, gibberellin A7, methyl-arylpyranone, docosapentaenoyl glycerophosphorylcholine, Cratoxyborenone E, heptanol, prenylflavonoids, pteridin-6-carboxylic acid and Garcimangosone B. The invention further discloses a preparation method of the metabolic marker composition. The metabolic marker combination provided by the invention can be used for carrying out production process traceability and authenticity identification on the high-calcium vegetable ox ear powder, and can be used as a basis for evaluating a product drying process quality standard and monitoring the consistency of a drying process.
Owner:江西省 中国科学院庐山植物园

Cyclodextrin complexes of specialized proresolving mediators

The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.
Owner:THETIS PHARMACEUTICALS LLC

Application of rhizoma smilacis glabrae in preparation of medicine for treating intestinal flora and / or metabolic disorder caused by hyperuricemia

The invention provides application of rhizoma smilacis glabrae in preparation of a medicine for treating intestinal flora and / or metabolic disorder caused by hyperuricemia. The application is realized by regulating and controlling the expression level of SUA-associated metabolic markers in serum. The SUA-associated metabolic markers comprise: metabolites positively associated with SUA, wherein the metabolites comprise chenodeoxycholic acid, nutritional cholic acid, 7alpha-hydroxy-3-oxo-4-cholesteric acid and ceramyl ethanolamide; eight metabolites which are in negative correlation with SUA comprise polyterpene alcohol group-beta-D-glucosyl phosphate, docosapentaenoic acid, 5, 8, 11-eicosatrienoic acid, adrenoic acid, diacylglycerol DG (16: 0 / 22: 5), phosphatidylcholine PC (14: 0 / 18: 1), phosphatidylcholine PC (18: 0 / 22: 6) and retinyl ester.
Owner:SHANGHAI JIAOTONG UNIV

HA / CS / dECM-AD hydrogel medicine and application thereof in treatment of osteoarthritis

The invention belongs to the technical field of biological medicine, and particularly relates to a HA / CS / dECM-AD hydrogel medicine and application thereof in treatment of osteoarthritis, the hydrogel medicine is composed of a three-dimensional network composed of hyaluronic acid (HA), chitosan (CS) and a decellularized extracellular matrix (dECM), and two active ingredients of atorvastatin (Ato) and docosapentaenoic acid (DPA) are loaded in the three-dimensional network. The hydrogel has the following characteristics: a dual slow-release mechanism is adopted, Ato is quickly released within 2 hours, and DPA is accumulatively released by 70-90% within 7 days through PDA nanoparticles; according to biological activity induction, the dECM derived from hiPSCs retains cartilage specific components such as type II collagen (COL2) and aggregation protein glycan (ACAN), and cartilage cell proliferation is promoted; and the retention time in the articular cavity exceeds 6 weeks. Animal experiments show that the hydrogel can remarkably repair cartilage defects, inhibit M1 type macrophage infiltration and reduce expression of proinflammatory factors such as IL-1beta and TNF-alpha.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV

Lipid comprising docosapentaenoic acid

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:NUSEED NUTRITIONAL AUSTRALIA PTY LTD +2

Serological biomarkers for diagnosing chronic obstructive pulmonary disease

The invention relates to the technical field of biomedicine, in particular to a serological biomarker for diagnosing chronic obstructive pulmonary disease. The marker is selected from the group consisting of myristic acid, oleic acid, stearic acid, eicosapentaenoic acid, arachidic acid, docosahexaenoic acid, docosapentaenoic acid, docosatetraenoic acid, nervonic acid, wood tar acid, arginine and glutamine. The combined marker has relatively high sensitivity and specificity, can provide reliable diagnosis information in an early stage or an atypical stage of symptoms, and overcomes the limitations of dependence on lung function detection, insufficient sensitivity, complex operation and the like of the existing diagnosis means; therefore, a convenient and accurate detection tool capable of being popularized is provided for early screening, risk prediction and clinical diagnosis of the chronic obstructive pulmonary disease.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Brassica Plants Producing Elevated Levels of Polyunsaturated Fatty Acids

Provided herein are Brassica plants that produce one or more of omega-3 docosapentaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA), and methods of making such plants.
Owner:BASF PLANT SCI GMBH

Lipid comprising docosapentaenoic

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:GRAINS RES & DEV CORP +2

Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids

The present invention relates to lipid comprising docosapentaenoic acid and / or docosahexaenoic acid wherein the docosapentaenoic acid and / or docosahexaenoic acid may be preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.
Owner:GRAINS RES & DEV CORP +1

Lipid comprising docosapentaenoic

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:COMMONWEALTH SCI & IND RES ORG +2

Lipid comprising docosapentaenoic acid

PendingUS20260201267A1BiotechnologyMicrobiology
The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:COMMONWEALTH SCI & IND RES ORG +2